Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused o...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a r...
MediWound is a fully integrated biopharmaceutical company focused on developing, m...
MediWound is a fully integrated biopharmaceutic...
Valeritas is a commercial-stage medical technology company focused on improving he...
Valeritas is a commercial-stage medical technol...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakal...
Correvio has two marketed, in-hospital, cardiol...
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing thera...
At Catabasis Pharmaceuticals, our mission is to...
Join the National Investor Network and get the latest information with your interests in mind.